Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mereo Biopharma Group Plc ADR (MREO)

Mereo Biopharma Group Plc ADR (MREO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,922
  • Shares Outstanding, K 159,132
  • Annual Sales, $ 500 K
  • Annual Income, $ -41,880 K
  • EBIT $ -47 M
  • EBITDA $ -47 M
  • 60-Month Beta 0.43
  • Price/Sales 105.03
  • Price/Cash Flow N/A
  • Price/Book 1.28
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings $-0.01 on 03/19/26
  • Next Earnings Date 05/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 274.92% (+25.52%)
  • Historical Volatility 53.19%
  • IV Percentile 68%
  • IV Rank 40.52%
  • IV High 577.43% on 02/02/26
  • IV Low 68.88% on 08/20/25
  • Expected Move (DTE 14) 0.0425 (13.28%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 398
  • Volume Avg (30-Day) 298
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 29,123
  • Open Int (30-Day) 31,114
  • Expected Range 0.2775 to 0.3625

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.01
  • Number of Estimates 2
  • High Estimate $0.04
  • Low Estimate $-0.01
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) +150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3101 +3.19%
on 03/30/26
0.4199 -23.79%
on 03/04/26
-0.0775 (-19.50%)
since 03/02/26
3-Month
0.3101 +3.19%
on 03/30/26
0.7800 -58.97%
on 01/14/26
-0.1904 (-37.30%)
since 01/02/26
52-Week
0.2000 +60.00%
on 12/29/25
3.0500 -89.51%
on 07/09/25
-2.0500 (-86.50%)
since 04/02/25

Most Recent Stories

More News
MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ:...

MREO : 0.3200 (-3.03%)
MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options

MREO : 0.3200 (-3.03%)
DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026

PHILADELPHIA , April 2, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ:...

MREO : 0.3200 (-3.03%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

MREO : 0.3200 (-3.03%)
Shareholders that lost money on Mereo BioPharma Group plc(MREO) should contact Levi & Korsinsky about pending Class Action - MREO

NEW YORK , April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO) of a class action securities lawsuit....

MREO : 0.3200 (-3.03%)
MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

NEW YORK , March 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO)...

MREO : 0.3200 (-3.03%)
MREO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Mereo BioPharma Group plc Securities Lawsuit -- The Gross Law Firm

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).

MREO : 0.3200 (-3.03%)
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 30, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Mereo BioPharma Group plc...

MREO : 0.3200 (-3.03%)
Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

LOS ANGELES , March 30, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations...

MREO : 0.3200 (-3.03%)
MREO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options

MREO : 0.3200 (-3.03%)

Business Summary

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company's rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated...

See More

Key Turning Points

3rd Resistance Point 0.3676
2nd Resistance Point 0.3574
1st Resistance Point 0.3387
Last Price 0.3200
1st Support Level 0.3098
2nd Support Level 0.2996
3rd Support Level 0.2809

See More

52-Week High 3.0500
Fibonacci 61.8% 1.9613
Fibonacci 50% 1.6250
Fibonacci 38.2% 1.2887
Last Price 0.3200
52-Week Low 0.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.